Comparing Ready-to-Use and Powder AbobotulinumtoxinA for Glabellar Lines: A Randomized, Controlled, Triple-Blinded...

Area of Science:

• Dermatology
• Aesthetic Medicine
• Neurology

Background:

• Botulinum toxin A (BoNT-A) is a leading treatment for glabellar lines.
• Limited data exist on the effectiveness of ready-to-use abobotulinumtoxinA (RTUaboBoNT-A) for this cosmetic indication.

Purpose of the Study:

• To compare the efficacy, durability, and safety of RTUaboBoNT-A versus standard abobotulinumtoxinA (aboBoNT-A).
• To evaluate RTUaboBoNT-A for treating moderate to severe glabellar wrinkles.

Main Methods:

• A randomized, triple-blinded trial involving 38 male volunteers aged 25-50.
• Participants received either aboBoNT-A or RTUaboBoNT-A, with assessments including EMG, wrinkle severity scales, and patient satisfaction.
• Data collected pre-injection and at 1, 2, 3, and 4 months post-injection.

Main Results:

• No significant differences were found between RTUaboBoNT-A and aboBoNT-A in EMG activity or glabellar line severity at any follow-up point.
• Patient satisfaction levels were comparable between the two treatment groups.
• The RTUaboBoNT-A group reported significantly higher pain intensity during the injection procedure.

Conclusions:

• RTUaboBoNT-A demonstrates comparable efficacy and durability to standard aboBoNT-A for glabellar line treatment.
• Both formulations are considered safe, though RTUaboBoNT-A may increase injection discomfort.
• RTUaboBoNT-A presents a viable alternative for glabellar wrinkle correction.